Amneal Pharmaceuticals, Inc. AMRX Proceeds from issuances of debt

Proceeds from issuances of debt at other companies

CencoraCOR

$4.54B+200%

Cardinal HealthCAH

——

Other financials

Income statement

See full

Revenue$722.5M+3.9%

Gross profit$320.1M+25.1%

Operating income$141.8M+41.3%

Net income$62.3M+411%

EPS (diluted)$0.19+375%

Balance sheet

See full

Cash & equivalents$197.7M+234%

Total debt$2.6B+17.7%

Total equity-$45.4M+65.5%

Total assets$3.5B+5.2%

Cash flow

See full

Operating cash flow-$26.7M-461%

CapEx$8.2M-37.9%

Free cash flow-$34.9M-507%

Valuation

See full

Market cap$5.17B+51.0%

Enterprise value$7.55B+33.4%

P/E42.4×—

P/S1.7×+0.5×

Profitability

See full

Gross margin38.7%+2.0pp

Operating margin14.3%+1.6pp

Net margin4%+3.6pp

FCF margin7.9%-1.0pp

Returns & leverage

See full

Return on equity-52.8%-12.7pp

Debt / equity127.9×+119×

Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfDebt.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s proceeds from issuances of debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s proceeds from issuances of debt?: Amneal Pharmaceuticals, Inc. (AMRX) reported proceeds from issuances of debt of $134.67M in Q1 2026.